StreetAlpha.app
Home › Stocks › AVIR

Atea Pharmaceuticals, Inc. (AVIR)

$3.96
▼ −3.88%
LAST CLOSE · NOV 17

Atea Pharmaceuticals develops oral antiviral medicines for hepatitis C and hepatitis E, and none are yet approved. It last closed at $3.96 on Nov 17, down 3.88% on the day. AVIR last reported earnings on Wed, Aug 12, 2026.

AI Auto Pilots
Is AVIR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$155.4M
EPS (diluted)
−$1.95
Valuation
Market cap
$318.0M
80.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$97.9M
At Sep 30
Shareholder equity
$175.7M
Shares outstanding
80.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $121.2M$121.2MFY2021FY2022: −$115.9M−$115.9MFY2022FY2023: −$136.0M−$136.0MFY2023FY2024: −$168.4M−$168.4MFY2024FY2025: −$158.3M−$158.3MFY2025

From AVIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Aug 12
2026 · After the close (AMC)
Reported EPS
-$0.41
vs -$0.56 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±6.5%
Priced in before that report
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated AVIR in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 102.0% upside

Based on 1 analyst who set a price target on AVIR in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $3.96.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $3.96
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
Morgan StanleyTarget raised
Nov 16Hold$7 → $8
Morgan StanleyMaintained
Aug 13Hold$7
DateFirmActionRatingPrice target
Nov 16Morgan StanleyTarget raisedHold$7 → $8
Aug 13Morgan StanleyMaintainedHold$7
Loading…

Technical Analysis

AVIR · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 6% below its 20 day and 19% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Nov 2) at $3.94, and the nearest resistance the Pivot at $3.98.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 6.2%/day
Key levels
$6.4552 week high+62.9%
$4.95200 day average+25.0%
$4.89100 day average+23.5%
$4.7350 day average+19.4%
$4.48Swing high (Nov 9)+13.1%
$4.1920 day average+5.8%
$4.11Pivot R1+3.8%
$3.98Pivot+0.5%
$3.96Last close
$3.94Swing low (Nov 2)−0.5%
$3.83Pivot S1−3.3%
$2.9252 week low−26.3%
Indicators
RSI (14)36.40Weak, oversold below 30Neutral
MACD-0.15Above its signal lineBullish
Stochastic37.5Middle of its rangeNeutral
ADX (14)25.8Trending down
Williams %R-83.1Oversold below −80, overbought above −20Oversold
CCI (20)-184.3Oversold below −100, overbought above 100Oversold
Rate of change−5.0%Change over 10 sessionsBearish
ATR (14)$0.25Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVIR

What happened before

See how AVIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AVIR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AVIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AVIR in the last 90 days.

Loading…

See today’s whale options flow across the market →

AVIR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲59 buying vs 48 selling
  • ▼Held by funds -0.5 pts
  • ●Funds holding +1
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding127126+0.8%
In funds' top 10110.0%
Held by funds73.5%74.0%−0.5 pts
New / increased14 / 4519 / 45−7.8%
Reduced / sold out36 / 1238 / 20−17.2%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVIR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVIR is in one of them and how their past AVIR trades turned out.

AVIR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVIR in an article yet. Here's the latest on the wider market.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. It is developing oral antiviral medicines for serious viral diseases. Its main candidates are a two drug regimen for hepatitis C, which is still in clinical trials, and a treatment for hepatitis E in patients with weakened immune systems. The company builds these candidates from a proprietary platform of nucleotide compounds.

Headquarters
Boston, MA